Fly News Breaks for February 14, 2020
Feb 14, 2020 | 06:13 EDT
BofA analyst Jason Gerberry downgraded Alkermes to Neutral from Buy with a $20 price target, down from $31 prior. The analyst cites his expectations for slowing volume growth for the company's core brands - Vivitrol in addiction and Aristada in schizophrenia - as well as a negative mix shift and net price headwinds. Gerberry also sees Alkermes' main pipeline assets still being a couple of years away from becoming value unlocking catalysts for the stock.
News For ALKS From the Last 2 Days
There are no results for your query ALKS